Intralesional rituximab in the treatment of indolent primary cutaneous B-cell lymphoma.

Intralesional rituximab in the treatment of indolent primary cutaneous B-cell lymphoma.
Br J Dermatol. 2020 Aug 15;:
Authors: Chirico A, Henderson Berg MH, Roberge D, Pehr K
Abstract
Primary cutaneous B-cell lymphomas (PCBCLs) are a heterogeneous group of extranodal lymphomas1 . Primary cutaneous marginal zone lymphoma (MZL) and follicle center lymphoma (FCL), the most prevalent PCBCLs, are typically indolent.
PMID: 32798319 [PubMed - as supplied by publisher]

Source: The British Journal of Dermatology - August 14, 2020 Category: Dermatology Authors: Chirico A, Henderson Berg MH, Roberge D, Pehr K Tags: Br J Dermatol Source Type: research